Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma

ABSTRACT: Inevitable relapses remain as the major therapeutic challenge in patients with mantle cell lymphoma (MCL) despite FDA approval of multiple targeted therapies and immunotherapies. Fc gamma receptors (FcγRs) play important roles in regulating antibody-mediated immunity. FcγRIIB, the unique i...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Vivian Changying, Liu, Yang, Jordan, Alexa, Leeming, Angela, McIntosh, Joseph, Huang, Shengjian, Zhang, Rongjia, Cai, Qingsong, Chen, Zhihong, Li, Yijing, Che, Yuxuan, Nie, Lei, Karlsson, Ingrid, Mårtensson, Linda, Kovacek, Mathilda, Teige, Ingrid, Frendéus, Björn, Wang, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996600/
https://www.ncbi.nlm.nih.gov/pubmed/35410313
http://dx.doi.org/10.1186/s13045-022-01257-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996600/
https://www.ncbi.nlm.nih.gov/pubmed/35410313
http://dx.doi.org/10.1186/s13045-022-01257-9

Ejemplares similares